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CASE REPORT
Thromboelastography-guided transfusion 
in dogs with hypocoagulable disorders: a case 
series
Rebecca Langhorn* , Louise Bochsen, Jakob Lundgreen Willesen, Tina Møller Sørensen 
and Annemarie Thuri Kristensen
Abstract 
Background: Thromboelastography (TEG) is a global whole blood hemostasis assay which includes plasma as well as 
cellular components of hemostasis in the analysis and follows the quality and dynamics of clot development, stabili-
zation, and lysis. In human medicine TEG is also a valuable asset in the therapeutic setting, allowing evaluation of the 
effect of transfusion therapy in vitro. This case series describes the use of TEG as a guiding tool for transfusion therapy 
in four dogs with hypocoagulable hemostatic disorders.
Case presentation: Four dogs presented with hypocoagulable disorders of hemostasis, diagnosed as rodenticide 
intoxication, angiostrongylosis, disseminated intravascular coagulation following severe systemic inflammation, and 
immune-mediated thrombocytopenia, respectively. TEG was used as a diagnostic tool as well as a guiding tool in the 
decision of whether or not, and in what dose, fresh frozen plasma would be of benefit in the treatment protocol for 
each dog.
Conclusions: TEG may be applied in the therapeutic setting as a means to tailor individual patient transfusion 
therapy in critically ill dogs with hypocoagulable states.
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Background
Bleeding disorders represent a common challenge to the 
companion animal veterinarian with a need for thor-
ough and timely diagnostic work-up and therapy due to 
the often hemodynamically unstable state of the patient. 
With the traditional plasma-based coagulation assays, 
such as prothrombin time (PT) and activated partial 
thromboplastin time (aPTT), only the effect of plasma 
coagulation factors on initiation of hemostasis is meas-
ured, and the analysis ends at the point of fibrin polymer 
formation. In addition, prolonged aPTT and PT do not 
necessarily correlate with bleeding risk [1–3]. Throm-
boelastography (TEG), on the other hand, is a global 
whole blood hemostasis assay, including plasma as well 
as cellular components of hemostasis and following the 
quality and dynamics of clot development, stabilization, 
and lysis [4]. Additionally, it has higher negative as well 
as positive predictive values for identification of patients 
with clinical bleeding when compared to conventional 
coagulation assays [1]. With the validation of the assay 
for use in dogs, TEG has, therefore, become a valuable 
diagnostic tool in the work-up of bleeding disorders in 
this species [5].
Interestingly, human studies have revealed that TEG 
may also be of value in the therapeutic setting, allowing 
evaluation of the effect of transfusion therapy in vitro [6]. 
This is a method for evaluation of the potential individual 
patient response to a transfusion, thereby avoiding exces-
sive transfusion therapy and the risk of transfusion reac-
tions in patients for whom a transfusion is not beneficial 
as well as optimizing the use of blood components [7].
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This case series reviews four dogs with different hypo-
coagulable disorders and the use of TEG in guiding their 
therapy. The cases were seen between 2008 and 2017 at 
the University Hospital for Companion Animals, Univer-
sity of Copenhagen, and are a representative sample of 
the patient population for which the authors have applied 
TEG-guided transfusion over more than a decade. The 
cases presented were chosen based on two criteria: (1) 
Cases with different hypocoagulability disorders in order 
to present TEG-guided transfusion across a range of 
patient types (2) Cases for which a full admission data set 
(clinical and paraclinical results) as well as post-transfu-
sion TEG were available.
In each case TEG analyses were performed using the 
computerized thromboelastograph (TEG 5000 Hemo-
stasis Analyzer) and applying recombinant human tis-
sue factor (TF) for activation according to a previously 
validated method [5]. The analysis is performed only by 
skilled personnel at the Veterinary Diagnostic Labora-
tory, University of Copenhagen, and is applied routinely 
in the investigation of hemostatic abnormalities at the 
hospital. Briefly, citrated whole blood is collected using a 
vacutainer system. After letting the blood rest for 30 min, 
it is inverted carefully 10 times, and the assay is initiated 
by activation of 400 µL whole blood with 25 µL diluted 
TF [Innovin (Dade Innovin, Siemens)]. Then, 340  µL of 
the TF-activated blood are transferred to a preheated 
(37 °C) TEG cup containing 20 µL 0.2 M  CaCl2 and a final 
TF dilution of 1:50,000 [5]. The TEG assay is set to run 
for 2  h, however transfusion requirement can often be 
suspected within the first 30 min of the analysis. When 
evaluating the benefit of fresh frozen plasma (FFP) for a 
dog, a new TEG is initiated with addition of FFP in vitro 
(FFP-TEG). 50 µL FFP added to the 400 µL citrated whole 
blood corresponds to a clinical dose of 10  mL/kg FFP 
transfusion for a dog with a blood volume of 80  mL/kg 
(i.e. approximately 10%). The 340 µL sample volume of 
TF-activated blood for the FFP-TEG is drawn from this 
mixture.
The TEG parameters relevant for evaluating hypocoag-
ulability are the reaction time (R) which reflects initiation 
of coagulation and relies on adequate concentrations of 
coagulation factors, the kinetics of coagulation reflected 
by the angle (α) and kinetics (K) which rely on both coag-
ulation factors, fibrinogen and platelets, and the maximal 
amplitude (MA) which reflects final clot strength and 
depends on platelets and fibrinogen concentration [5].
Case presentation
Case 1
A 3-year-old 9.9  kg neutered male mixed-breed dog 
presented with a history of a dry cough and sudden 
deterioration. The referring veterinarian had suspected 
pneumonia based on thoracic radiographs, and the dog 
had been treated with antibiotics and a non-steroidal 
anti-inflammatory drug prior to referral. The veterinar-
ian had also tested the dog for Angiostrongylus vaso-
rum (endemic in the area), for which a fecal smear and 
the commercially available antigen test (IDEXX Angio 
Detect™) were negative.
On presentation the dog was depressed, but inter-
ested in its surroundings and able to stand and walk on 
its own. Initial vital signs included a rectal temperature 
of 38.1 °C, a heart rate of 120 beats/min, and a resting 
respiratory rate of 44 breaths/min. Reduced vesicular 
sounds were heard bilaterally on pulmonary auscul-
tation. Mucous membranes were pale with a slightly 
prolonged capillary refill time. Emergency blood work 
was performed, and the CBC revealed a severe non-
regenerative anemia with a hematocrit of 0.19 (see 
Table 1 for reference intervals). A mild thrombocytope-
nia with a platelet count of 182 × 109/L was also noted. 
The leukogram and the biochemical profile (measur-
ing alanine aminotransferase, alkaline phosphatase, 
gamma-glutamyl transferase, glucose, urea, creatinine, 
cholesterol, bilirubin, total protein, albumin, calcium, 
phosphate, sodium, and potassium) were unremark-
able. C-reactive protein (CRP) was below the clinical 
decision limit applied at the laboratory (25 mg/L). Tho-
racic radiographs were performed, revealing moderate 
pleural effusion and areas of suspected consolidation. A 
coagulation panel and a TEG were requested, and the 
dog was taken directly to ultrasound for thoracic and 
abdominal evaluation in order to locate a focus for sus-
pected hemorrhage. An ultrasound-guided diagnostic 
and therapeutic thoracocentesis was performed, reveal-
ing a hemorrhagic effusion (PCV 0.27). No underly-
ing cause was detected. Abdominal ultrasound was 
Table 1 Reference intervals for  reported hematological 
and coagulation parameters
PT prothrombin time; aPTT activated partial thromboplastin time
a Platelet counts were confirmed by evaluation of a blood smear unless 
otherwise stated
b PT measurements simultaneously performed on a healthy control pool: 
7.7–9 s
c aPTT measurements simultaneously performed on a healthy control pool: 
11.8–13.3 s
Hematocrit 0.39–0.59
Platelets 200–500 × 109/La
Fibrinogen 1–4 g/L
Eosinophils 0–1.2 × 109/L
PT Within 25% of reference  poolb
aPTT Within 25% of reference  poolc
d-dimer 0–0.5 mg/L
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unremarkable. The dog was hospitalized in an oxygen 
cage, providing 33% oxygen.
Results of the coagulation panel revealed an unmeas-
urably long PT (> 320  s), prolonged aPTT (33.4  s), 
unmeasurably low fibrinogen < 0.6 g/L, and a d-dimer of 
0.3 mg/L. The TEG flat-lined (Fig. 1a), showing an infinite 
R corresponding to lack of clot formation. An FFP-TEG 
with the in vitro addition of 50 µL FFP, corresponding to a 
10 mL/kg FFP transfusion, was performed. This resulted 
in a hypercoagulable tracing (Fig.  1a, Table  2), improv-
ing all TEG parameters, thus implying that transfusion of 
10 mL/kg of FFP would be beneficial and sufficient. On 
further interview with the owner, it was discovered that 
the rodenticides floucoumafen and bromadiolone were 
continuously used at their home property. Hence, a ten-
tative diagnosis of rodenticide intoxication was made.
Ten mL/kg of FFP was administered according to the 
amount predicted sufficient by the FFP-TEG, and the 
dog was started on vitamin K1 therapy (5 mg/kg). A TEG 
was repeated following the transfusion, showing a trac-
ing corresponding to that predicted by the pre-treatment 
FFP-TEG (Fig. 1a, Table 2).
The following day the dog was bright, alert, and respon-
sive. Mild tachypnea remained (44 breaths/min), but the 
dog did not deteriorate when taken out of the oxygen 
cage. On a repeated ultrasound examination, the amount 
of fluid in the pleural space was subjectively evaluated 
as similar to that seen the previous day following thora-
cocentesis. A CBC was repeated, revealing a hematocrit 
of 0.17, and a normalized platelet count (209 × 109/L). A 
repeated TEG was normocoagulable. The dog was kept 
in the hospital for observation until the following day at 
which time it was clinically stable, and the hematocrit 
had increased to 0.24. The dog was discharged on vita-
min K1 treatment for 5 weeks. Follow-up visits revealed a 
normalized hematocrit and a continually normal coagu-
lation status as evidenced by normal TEG parameters.
Case 2
A 1-year-old 27.5  kg intact male Vizsla presented with 
acute neurological signs characterized by ataxia and 
decreased awareness of its surroundings. The dog had 
been seen by its regular veterinarian the previous day 
due to depression and coughing, and the veterinarian had 
prescribed a combination of spot-on moxidectin and imi-
dacloprid (Advocate© Bayer Animal Health) due to sus-
picion of angiostrongylosis.
At presentation the dog was in lateral recumbency. 
When encouraged to stand and walk, it was ataxic. Men-
tally, the dog was responsive, but star-gazing behavior 
and signs of left-sided hemineglect (decreased awareness 
of being approached from one side even though vision 
appeared to be present) were noted. Vital signs included 
a rectal temperature of 38.4 °C, a heart rate of 80 beats/
min, and a respiratory rate of 24 breaths/min. Increased 
vesicular sounds were noted on pulmonary auscultation. 
Cutaneous petechiae were detected in the left groin and 
axilla. A mean arterial blood pressure of 94 mmHg was 
obtained.
Hematological, biochemical, and coagulation pan-
els and a TEG were performed as were thoracic radio-
graphs, a fecal smear, and the IDEXX Angio Detect™ test. 
A moderate non-regenerative anemia with a hematocrit 
of 0.28 and a moderate thrombocytopenia (119 × 109/L) 
was found on the CBC. Biochemistry was unremarkable. 
CRP was moderately elevated. The coagulation panel 
revealed a mildly prolonged PT (12.8 s), a normal aPTT, 
a low fibrinogen (0.94  g/L), and an increased d-dimer 
(1.2  mg/L). The TEG (Fig.  1b, Table  2) was hypoco-
agulable (mildly prolonged R and K, low α and MA). A 
FFP-TEG with in vitro addition of 50 µL FFP resulted in 
normalizing of R, K, and α, with mild-moderate improve-
ment in MA. An additional FFP-TEG with addition of 75 
µL FFP (corresponding to 15 mL/kg FFP) showed negli-
gible additional improvement of the MA. The antigen 
test as well as the fecal smear confirmed infection with 
A. vasorum. Thoracic radiographs revealed a generalized 
markedly increased interstitial pattern.
The dog was diagnosed with angiostrongylosis with 
a secondary coagulopathy, and it was suspected that its 
neurological signs were the result of a cerebral vascular 
event although larva migrans or a separate primary neu-
rological problem could not be ruled out. A FFP trans-
fusion of 10  mL/kg was administered, according to the 
amount predicted as optimal by the FFP-TEG, along with 
prednisolone (0.5  mg/kg SID for 3  days) for prevention 
of anaphylaxis following parasite death. After transfu-
sion of the initial 10 mL/kg, another TEG was performed, 
revealing improvement on all parameters, but not to the 
extent seen in vitro, presumably due to ongoing pathol-
ogy. Therefore, the transfusion was continued, however, 
following a total amount of 15 mL/kg, the dog developed 
a suspected mild transfusion reaction characterized by 
edema of the muzzle and palpebrae which responded 
to antihistamine treatment (mepyramine 1  mg/kg 
subcutaneously).
During the first 24  h ataxia resolved, and the dog 
seemed more mentally aware, but additional petechiae 
were noted in the groin and axilla, and more appeared 
over the course of the second day. A repeated TEG 
revealed a return to the state of the initial TEG. As the 
dog had developed more petechiae, it was concluded 
that additional transfusion therapy was needed. Due 
to the previous transfusion reaction, a different donor 
was chosen, and, also, cryoprecipitate treatment was 
decided upon in order to minimize the amount of plasma 
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Fig. 1 Thromboelastography-guided transfusion of four dogs with hypocoagulable disorders. a Dog with rodenticide poisoning (case 1): 
Thromboelastography (TEG) was performed at admission (black line) at which point the tracing flat-lined. A TEG with in vitro addition of 50 µL 
fresh frozen plasma (FFP-TEG), corresponding to a 10 mL/kg FFP transfusion, was shown to markedly improve the tracing (green line). Following 
a FFP transfusion of 10 mL/kg, a post-transfusion TEG (pink line) showed results similar to the FFP-TEG. b Dog with angiostrongylosis (case 2): 
TEG was performed at admission (black line) showing hypocoagulability. A FFP-TEG with addition of 50 µL FFP was shown to normalize R, K, 
and α and to improve MA (green line). A FFP-TEG with 75 µL FFP showed negligible additional improvement (pink line). Following transfusion 
with 10 mL/kg FFP, a post-transfusion TEG showed improved results (brown line), although not quite to the extent predicted in vitro, likely due 
to ongoing consumption of coagulation factors. c Dog with suspected disseminated intravascular coagulation (case 3): TEG was performed at 
admission (black line), showing severe hypocoagulability. A FFP-TEG with addition of 50 µL FFP was shown to improve, although not normalize 
all parameters of the TEG (green line). A FFP-TEG with 100 µL FFP showed no additional improvement (pink line). Following an FFP transfusion of 
10 mL/kg, a post-transfusion TEG (brown line) showed results similar to the FFP-TEG. d Dog with primary immune-mediated thrombocytopenia 
(case 4): TEG was performed at admission (black line), showing severe hypocoagulability. A FFP-TEG with addition of 50 or 100 µL FFP did not cause 
any improvement (green and pink lines). The dog was provided with a fresh whole blood (WB) transfusion, and post-transfusion TEG revealed 
improvement, although not normalization of all TEG parameters (brown line). A follow-up TEG 3 days later revealed normalization of the tracing 
(blue line)
Page 5 of 8Langhorn et al. Acta Vet Scand           (2019) 61:35 
administered while still supplying coagulation factors, 
especially fibrinogen as the dog had presented with 
hypofibrinogenemia. Still, another similar mild transfu-
sion reaction occurred following this transfusion. It was 
also decided to initiate fenbendazole treatment (25  mg/
kg SID for 21  days) [8] although the dog had already 
received moxidectin/imidaclopride from its referring vet. 
The addition of fenbendazole was chosen because of the 
authors’ experience with and available evidence for this 
treatment protocol in the sub-group of A. vasorum posi-
tive dogs with secondary coagulopathies [9].
The following day the dog had improved further, but 
intermittent neurological signs were seen (similar to 
those at presentation). A repeated CBC revealed a hema-
tocrit of 0.31, a platelet count of 175 × 109/L, as well as 
mild eosinophilia (1.8 × 109/L). A repeated TEG showed 
normalization of R, K, α, and MA, but with mildly 
increased LY30 and LY60 (percent fibrinolysis 30 and 
60  min after MA), corresponding to mildly increased 
fibrinolysis. The dog was, therefore, kept in hospital for 
observation. The following day the dog was clinically 
unremarkable, no further petechiae were observed, PT 
and aPTT were normal, and the dog was discharged. 
The owner noted intermittent star-gazing behavior the 
first few days following discharge, and, therefore, the 
prednisolone treatment was prolonged for another week 
and then tapered. The dog continued to improve, and a 
Baermann fecal analysis performed 2 weeks after the end 
of treatment was negative.
Case 3
A 10-year old 28.7  kg male neutered mixed-breed dog 
presented for a follow-up visit after having been hospi-
talized for 24  h the previous week with severe hemor-
rhagic gastroenteritis and hypovolemic shock. Prior to 
this episode the dog had been on 0.35 mg/kg oral predni-
solone daily for months due to dermatological problems 
(described by the client as pruritus). This treatment had 
been stopped at the initial presentation with gastroen-
teritis. The dog’s coagulation status (PT, aPTT, TEG) had 
been unremarkable during hospitalization apart from a 
moderate thrombocytopenia (65 × 109/L) which had not 
been confirmed microscopically. On presentation at the 
control visit the dog was bright, alert, and responsive, 
was eating and drinking normally, and the owner consid-
ered it to have recovered except for still having slightly 
soft stools. The dog was still receiving treatment with 
antibiotics and gastroprotectives.
The clinical exam was unremarkable. A hematologi-
cal profile was analyzed, revealing a platelet count of 
Table 2 Thromboelastography data from four dogs with hypocoagulable hemostatic disorders
Data is presented as baseline data (admission), investigation of the effect of fresh frozen plasma on the patient’s hemostatic state, and post-transfusion data
TEG thromboelastogram, FFP fresh frozen plasma, WB whole blood, R reaction time, K kinetics, α angle, MA maximal amplitude, min minutes, mm millimeters
Parameter R (min) K (min) α (degrees) MA (mm)
Reference intervals (3.0–9.0) (2.0–8.0) 28.0–59.0 39.0–59.0
Case 1
 Admission TEG > 120 Not reached Not reached Not reached
 FFP-TEG (50 µL FFP) 5.7 1.3 71.5 75.2
 Post-transfusion TEG 5.6 1.9 66.1 73.9
Case 2
 Admission TEG 10.1 15.6 20.2 27.2
 FFP-TEG (50 µL FFP) 7.1 5.7 38.4 37.4
 FFP-TEG (75 µL FFP) 7.0 4.8 41.2 39.0
 Post-transfusion TEG 9.5 7.9 29.8 32.6
Case 3
 Admission TEG 11.8 Not reached 7.9 7.4
 FFP-TEG (50 µL FFP) 7.3 15.8 23.8 22.3
 FFP-TEG (100 µL FFP) 6.9 20.2 20.0 20.8
 Post-transfusion TEG 6.3 11.7 28.9 25.7
Case 4
 Admission TEG 5.4 Not reached 27.1 8.7
 FFP-TEG (50 µL FFP) 5.0 Not reached 37.4 9.8
 FFP-TEG (100 µL FFP) 4.7 Not reached 40.2 10.0
 Post-transfusion TEG (WB) 4.6 6.2 44.1 32.5
 Follow-up TEG 5.6 2.8 54.8 53.5
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46 × 109/L, a mild non-regenerative anemia (hema-
tocrit 0.37) and mild eosinophilia (1.59 × 109/L). Bio-
chemistry was unremarkable. CRP was below 25 mg/L. 
A coagulation profile and a TEG were requested in 
order to further evaluate the patient’s hemostatic state 
and possible need for transfusion therapy, revealing an 
aPTT of 18  s, unmeasurable PT and fibrinogen, and a 
d-dimer of 3.7 mg/L. The TEG (Fig. 1c, Table 2) showed 
severe hypocoagulability (prolonged R, decreased α and 
MA; K was not reached). A FFP-TEG with the in vitro 
addition of 50 µL FFP was performed, leading to 
improvement of all parameters, but without complete 
normalization of the coagulation status. An additional 
FFP-TEG with 100 µL FFP (corresponding to 20  mL/
kg FFP) did not result in further improvement. A von 
Willebrand factor analysis was also performed with 
a result of 68%. This assay was calibrated on a plasma 
pool from healthy dogs and the sample result extrapo-
lated from the standard curve and reported as percent-
age with > 70% considered the normal range and < 50% 
considered abnormal.
It was considered most likely that the dog had devel-
oped disseminated intravascular coagulation (DIC) sec-
ondary to the severe systemic inflammatory reaction it 
had suffered the previous week. A secondary immune-
mediated thrombocytopenia could not be ruled out. To 
rule out other underlying causes the dog was tested for 
tick-borne agents (serology for Borrelia sp., Anaplasma 
sp., and Erhlichia sp. measured with IDEXX 4dx) and 
gastrointestinal parasites (Giardia sp. and Cryptosporid-
ium sp.), all of which were negative. A Baermann fecal 
analysis was performed, in which one larva, considered 
to be a Crenosoma vulpis larva, was found, but A. vaso-
rum could not be completely ruled out due to the qual-
ity of the larva (an antigen test was not commercially 
available at this time). The dog had no history of exercise 
intolerance or coughing, and thoracic radiographs were 
unremarkable. As the dog had a history of skin prob-
lems which had previously responded to prednisolone, 
an antinuclear antibody test was also performed and was 
negative.
While the suspected DIC was subclinical at this stage, 
the hypocoagulability detected by TEG was considered 
of importance because it is a known negative prognos-
tic factor for dogs with DIC [4]. Hence, as benefit of FFP 
transfusion was revealed by the FFP-TEG, this treat-
ment was considered indicated. A transfusion of 10 mL/
kg of FFP was administered, according to the amount 
predicted as optimal by the FFP-TEG. The dog was also 
started on fenbendazole in order to treat possible angi-
ostrongylosis. A subsequent TEG revealed a tracing cor-
responding to the one predicted by the FFP-TEG. The 
dog remained clinically stable and was discharged. Final 
follow-up visits revealed normalization of all parameters 
of hemostasis.
Case 4
An 8-year-old male 19.0 kg English Springer Spaniel pre-
sented with severe thrombocytopenia. Two months pre-
viously the dog had been diagnosed with a hepatopathy 
of unknown origin and a concurrent, possibly related, 
systemic inflammatory reaction. This had subsided on 
symptomatic treatment (antibiotics, antiemetics, and 
antioxidants), with almost total normalization of liver 
enzymes. The dog had been doing well since, but had 
developed a swelling on the chest following exercise the 
day before presentation. Antibiotics and antiemetics had 
been stopped 2 months and antioxidants 3 weeks prior to 
presentation.
At presentation the dog was quiet, alert, and respon-
sive. Vital signs included a rectal temperature of 38.4 °C, 
a heart rate of 102 beats/min, and a respiratory rate of 32 
breaths/min. Mucous membranes were pink and moist, 
but with evidence of petechiae on the gingiva. Cutaneous 
ecchymoses were similarly noted. The dog had a mean 
arterial pressure of 75 mmHg.
Hematological, biochemical, and coagulation pan-
els as well as a TEG were requested. The dog was tested 
for A. vasorum on fecal smear and antigen test, both of 
which were negative. Serologic testing for Erhlichia sp., 
Anaplasma sp., and Borrelia sp. (IDEXX 4dx) was also 
performed and was negative. Abdominal ultrasound and 
thoracic radiographs were desired, but postponed as 
simply touching the dog was enough to induce further 
ecchymoses.
The CBC revealed a severe thrombocytopenia 
(8 × 109/L) and was otherwise unremarkable, as was 
the biochemistry. CRP was below 25  mg/L. PT, aPTT, 
D-dimer, and fibrinogen were all unremarkable, but the 
TEG showed marked hypocoagulability (Fig. 1d, Table 2) 
characterized solely by a severely decreased MA. Per-
forming FFP-TEG with in vitro addition of 50 and 100 µL 
FFP, respectively, did not lead to any change in the TEG 
tracing, leading to the conclusion that the bleeding dis-
order was caused simply by the severe thrombocytopenia 
without any complicating coagulopathy, and that supply-
ing additional coagulation factors (including fibrinogen, 
an important contributor to the MA) would not ben-
efit the patient. Instead the dog was blood-typed and a 
fresh whole blood transfusion administered in order to 
supply platelets. A platelet concentrate product would 
have been preferable as the dog was not lacking plasma 
or erythrocytes; however such a product was not avail-
able. Following the whole  blood transfusion the platelet 
count had increased to 15 × 109/L, and an increase in the 
TEG MA was seen. At this point abdominal ultrasound 
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and thoracic radiographs were performed and were 
unremarkable.
The thrombocytopenia was considered to have a pri-
mary immune-mediated origin. No cause of a secondary 
immune-mediated reaction or increased platelet con-
sumption had been found on the diagnostic work-up, but 
a bone marrow disorder leading to decreased megakary-
ocyte production could not be ruled out. A therapeutic 
trial with immunosuppressive doses of corticosteroids 
was attempted. Two days after initiation of treatment the 
platelet count had increased to 38 × 109/L, with a simul-
taneous normalization of the TEG (Fig. 1d). As the dog 
was doing well and had not developed any further clini-
cal signs of bleeding, it was discharged on prednisolone 
2 mg/kg daily. The platelet count normalized within the 
next month, and steroid therapy was tapered.
Discussion and conclusions
With the introduction of the cell-based model of hemo-
stasis [10], viscoelastic assays such as TEG became 
widely used to deliver quantitative information on the 
entire hemostatic process including the clot formation, 
strength, life span, and break down. Unlike traditional 
assays they take into account both plasma and cellu-
lar elements of hemostasis. Their limitation in simulat-
ing hemostasis in vivo is mainly that they cannot detect 
the contribution of and abnormalities in the vascular 
endothelium, von Willebrand factor, platelet binding to 
the endothelium, or the shear forces of blood [7]. Hence, 
while the use of TEG may guide the clinician towards 
detection of hemostatic defects, it is important that the 
results be interpreted in the context of the patient’s clini-
cal condition [11]. An additional limitation of viscoelastic 
assays involves the effect of erythrocytes, with some evi-
dence to suggest that anemia confers a hypercoagulability 
to the assay [12]. As the patients described in this case 
series were all hypocoagulable, that is of less importance 
in the present context.
In human medicine TEG, or another viscoelastic assay 
known as the ROTEM (rotational thromboelastome-
try), are frequently used to guide transfusion therapy in 
trauma-induced coagulopathy [6]. Applying TEG along 
with transfusion algorithms has been shown to reduce 
transfusion requirements in trauma care [7]. Similarly, 
TEG-guided transfusion in post-operative care is fre-
quently used. A normal TEG in the context of post-
surgical bleeding thus indicates the need for surgical 
re-exploration of the site rather than transfusion therapy 
[7, 13]. In human medicine, applying the viscoelastic 
assays in this way allows for precision medicine with the 
right blood product (FFP, packed RBCs, platelet concen-
trate) administered in the right amount at the right time, 
minimizing the risk of adverse effects of transfusions, 
and optimizing the ethical use of blood products by lim-
iting unnecessary use. The success of these guidelines in 
human medicine might inspire investigation into similar 
application for veterinary patients.
The cases reviewed here represent a variety of hypoco-
agulable disorders in dogs and the use of TEG to achieve 
targeted replacement therapy of the individual patient. 
This use of TEG has not been previously reported in 
dogs, to the best knowledge of the authors. In the set-
up reported here, TF was applied as the activator. This is 
the standard activator used at the laboratory as it most 
closely simulates the in  vivo activation of coagulation. 
As kaolin-TEG is used for human TEG-guided transfu-
sion guidelines [6] it is possible that kaolin-activated FFP-
TEG would work for dogs as well, but future studies are 
required for confirmation.
The first case was a dog with rodenticide poisoning, 
known to affect the vitamin K-dependent coagulation 
factors by antagonizing vitamin K, thus rendering the 
liver unable to activate factors II, VII, IX, and X, ulti-
mately resulting in bleeding [14]. While it is well-estab-
lished that dogs with hemorrhage due to rodenticide 
poisoning benefit from FFP transfusions, TEG can play 
a greater role in these cases than simply affirming this 
fact. The in  vitro addition of FFP to the analysis allows 
a quantitative interpretation, hence evaluating the dose 
of plasma needed to achieve a normocoagulable state. In 
patients at increased risk of volume overload this has the 
added benefit of being able to provide as little colloid as 
necessary.
The second case presented with A. vasorum infection, 
a parasite known to cause hemorrhage in up to a third 
of affected patients [15]. The pathophysiological mecha-
nism in this case has not been clearly determined, but 
a low-grade, chronic DIC has been suspected, leading 
to depletion of both coagulation factors and platelets 
[15]. A recent study has revealed that a common cause 
of bleeding in these dogs may be hyperfibrinolysis [16], 
a hemostatic disorder which cannot be detected on 
standard coagulation testing, making TEG all the more 
useful to investigate the cause of bleeding and guide 
therapy in such animals. The dog in the present case 
did not have signs of hyperfibrinolysis on its baseline 
TEG, but did develop a mild hyperfibrinolysis during its 
hospitalization.
The third case was a dog with suspected DIC, a com-
plex hemostatic disorder in which an imbalance exists 
between the pro- and anticoagulant systems [4], and 
for which treatment is not straight-forward. In this spe-
cific case the dog did not have clinical signs of bleed-
ing at the time of presentation, but was considered at 
high risk of deterioration due to its worsening throm-
bocytopenia and recent severe inflammatory disease. 
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It is possible that this dog would have recovered with-
out transfusion therapy. However, hypocoagulability 
as detected by TEG is a poor prognostic factor in dogs 
with DIC [4], and, as the FFP-TEG analysis supported 
a benefit of administering FFP to this dog, transfu-
sion therapy was, therefore, considered a beneficial 
approach.
The final case represented a pure platelet-related dis-
order in which no benefit of administrating FFP could 
be detected. These dogs are a challenge in veterinary 
medicine as we generally do not have platelet concen-
trates available. Thromboelastography was applied in 
this case to investigate whether additional hemostatic 
complications had occurred and whether supplying 
FFP with its supply of especially fibrinogen would be of 
benefit in optimizing clot strength. The assay revealed 
no benefit of FFP, and a fresh whole blood transfusion 
was, therefore, the only way of optimizing the dog’s 
hemostatic status by providing fresh platelets. Once the 
platelet count had increased, albeit minimally, no fur-
ther bleeding was detected, and the effect of immuno-
suppression had time to prevail.
In conclusion, this retrospective case-series indicates 
that the ability of TEG analysis to assist in providing 
targeted therapy and monitoring the bleeding risk of 
dogs with hypocoagulable disorders could be of benefit 
in the emergency setting. Larger prospective studies 
are required to evaluate whether such targeted therapy 
reduces the morbidity and mortality associated with 
bleeding disorders, and whether algorithms similar to 
those currently used in human patients are of value in 
guiding veterinary transfusion therapy [6].
Abbreviations
α: angle; aPTT: activated partial thromboplastin time; CRP: C-reactive protein; 
DIC: disseminated intravascular coagulation; FFP: fresh frozen plasma; FFP-TEG: 
thromboelastography with in vitro supplementation of FFP; K: kinetics; MA: 
maximal amplitude; PT: prothrombin time; R: reaction time; TEG: thromboelas-
tography; TF: tissue factor.
Acknowledgements
Not applicable.
Authors’ contributions
All authors were involved in the work-up of the individual patients. RL, LB, and 
ATK analyzed and interpreted the patient data for this report. All authors read 
and approved the final manuscript.
Funding
The authors declare that no funding has been obtained for this report.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article.
Ethics approval and consent to participate
This report has involved only retrospective evaluation of thromboelastography 
data and medical records.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Received: 24 September 2018   Accepted: 12 July 2019
References
 1. Wiinberg B, Jensen AL, Rozanski E, Johansson PI, Kjelgaard-Hansen M, 
Tranholm M, et al. Tissue factor activated thromboelastography correlates to 
clinical signs of bleeding in dogs. Vet J. 2009;179:121–9.
 2. Moorehead PC, Barrowman NJ, Cyr J, Ray J, Klaassen R, Menon K. A prospec-
tive study of the association between clinically significant bleeding in PICU 
patients and thrombocytopenia or prolonged coagulation times. Pediatr 
Crit Care Med. 2017;18:455–62.
 3. Cheng T, Mathews KA, Abrams-Ogg ACG, Wood RD. Relationship between 
assays of inflammation and coagulation: a novel interpretation of the canine 
activated clotting time Résumé. Can J Vet Res. 2009;73:97–102.
 4. Wiinberg B, Jensen AL, Johansson PI, Rozanski E, Tranholm M, Kristensen 
AT. Thromboelastographic evaluation of hemostatic function in dogs with 
disseminated intravascular coagulation. J Vet Intern Med. 2008;22:357–65.
 5. Wiinberg B, Jensen AL, Rojkjaer R, Johansson PI, Kjelgaard-Hansen M, 
Kristensen AT. Validation of human recombinant tissue factor-activated 
thromboelastography on citrated whole blood from clinically healthy dogs. 
Vet Clin Pathol. 2005;34:389–93.
 6. Johansson PI, Sørensen AM, Larsen CF, Windeløv NA, Stensballe J, Perner 
A, et al. Low hemorrhage-related mortality in trauma patients in a Level I 
trauma center employing transfusion packages and early thromboelastog-
raphy-directed hemostatic resuscitation with plasma and platelets. Transfu-
sion. 2013;53:3088–99.
 7. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboe-
lastography in clinical coagulation management and transfusion practice. 
Transfus Med Rev. 2012;26:1–13.
 8. Willesen JL, Kristensen AT, Jensen AL, Heine J, Koch J. Efficacy and safety of 
imidacloprid/moxidectin spot-on solution and fenbendazole in the treat-
ment of dogs naturally infected with Angiostrongylus vasorum. Vet Parasitol. 
2007;147:258–64.
 9. Chapman PS, Boag AK, Guitian J, Boswood A. Angiostrongylus vasorum infec-
tion in 23 dogs (1999–2002). J Small Anim Pract. 2004;45:435–40.
 10. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Hae-
most. 2001;85:958–65.
 11. Haas T, Goerlinger K, Grassetto A, Agostini V, Simioni P, Nardi G, et al. Throm-
boelastometry for guiding bleeding management of the critically ill patient: 
a systematic review of the literature. Minerva Anestesiol. 2014;80:1320–35.
 12. Smith SA, Mcmichael MA, Gilor S, Galligan AJ, Hoh CM. Correlation of 
hematocrit, platelet concentration, and plasma coagulation factors with 
results of thromboelastometry in canine whole blood samples. Am J Vet 
Res. 2012;73:789–98.
 13. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value 
of modified computerized thromboelastography and platelet function 
analysis for postoperative blood loss in routine cardiac surgery. Anesth 
Analg. 2003;96:51–7.
 14. Waddell LS, Poppenga RH, Drobatz KJ. Anticoagulant rodenticide screening 
in dogs: 123 cases (1996–2003). J Am Vet Med Assoc. 2013;242:516–21.
 15. Adamantos S, Waters S, Boag A. Coagulation status in dogs with natu-
rally occurring Angiostrongylus vasorum infection. J Small Anim Pract. 
2015;56:485–90.
 16. Sigrist NE, Hofer-Inteeworn N, Schefer RJ, Kuemmerle-Fraune C, Schnyder 
M, Kutter APN. Hyperfibrinolysis and hypofibrinogenemia diagnosed with 
rotational thromboelastometry in dogs naturally infected with Angiostron-
gylus vasorum. J Vet Intern Med. 2017;31:1091–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
